Results 281 to 290 of about 117,898 (292)

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

Lancet, The, 2004
Jaap Verweij, Paolo Giovanni Casali, John Zalcberg   +2 more
exaly  

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

Journal of Clinical Oncology, 2008
Charles D Blanke, Margaret von Mehren, Robert G Maki   +2 more
exaly  

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Leukemia, 2016
Andreas Hochhaus, Giuseppe Saglio
exaly  

Discontinuation of imatinib may be possible in chronic myelogenous leukemia

Ca-A Cancer Journal for Clinicians, 2011
exaly  

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

Cancer Cell, 2010
Leonard D Shultz, Tessa L Holyoake, Ravi Bhatia   +2 more
exaly  

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

Journal of Clinical Oncology, 2008
Robert G Maki, Cristina R Antonescu, Wen-Bin Ou   +2 more
exaly  

Imatinib and the long tail of targeted drug development

Nature Reviews Clinical Oncology, 2019
Benjamin G Carlisle, Jonathan Kimmelman
exaly  

Imatinib

Reactions Weekly, 2019
openaire   +2 more sources

Imatinib

Reactions Weekly, 2012
openaire   +1 more source

Imatinib

Reactions Weekly, 2004
openaire   +1 more source